Panacea Biotec Ltd (PANACEABIO)
₹441.20
Mkt cap
₹3,413 Cr
P/E ratio
—
P/B
3.24
Div yield
0.00%
ROE
−2.36%
ROCE
−2.44%
EPS (TTM)
—
Book value
₹136
52W range
296–608
Sector
Healthcare
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company [1]
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−27.40% from high₹441
₹296+49.03% from low₹608
Current
₹441.20
Prev close
₹442.05
Day
−0.19%
Price performance
1D
−0.19%
1W
−19.61%
1M
−20.82%
3M
+19.71%
6M
+15.21%
1Y
+0.83%
YTD
+16.15%
Financials
FRevenue, profit & margin
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 128.93 | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 | 141.13 | 165.19 | 166.75 | |
| Expenses | 134.60 | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 | 158.92 | 153.45 | 164.18 | |
| Operating Profit | -5.67 | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 | -17.79 | 11.74 | 2.57 | |
| OPM % | -4.40% | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% | -12.61% | 7.11% | 1.54% | |
| Other Income | 34.44 | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 | 9.10 | 5.05 | 5.26 | |
| Interest | 1.05 | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 | 2.14 | 1.85 | 1.20 | |
| Depreciation | 9.51 | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 | 8.34 | 8.45 | 7.88 | |
| Profit before tax | 18.21 | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 | -19.17 | 6.49 | -1.25 | |
| Tax % | 169.63% | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% | -26.92% | 40.06% | -20.00% | |
| Net Profit | -12.68 | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 | -14.01 | 3.89 | -1.00 | |
| EPS in Rs | -2.07 | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202672.48%Promoter
Promoters72.48%
FIIs1.60%0.24
DIIs1.96%0.11
Public23.96%0.35
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,862.80 | 35.82 | 4,46,948 | 0.86% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹6,713.50 | 67.94 | 1,78,222 | 0.45% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹4,516.20 | 69.74 | 1,52,849 | 0.84% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,440.10 | 30.56 | 1,16,338 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Dr Reddy's Labs | ₹1,350.50 | 26.86 | 1,12,723 | 0.59% | 221 | −86.14% | 7,546 | −11.51% | 13.64% |
| Zydus Lifesci. | ₹1,101.40 | 20.43 | 1,10,827 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.15% |
| Lupin | ₹2,343.50 | 18.59 | 1,07,152 | 0.51% | 1,469 | +101.49% | 7,475 | +31.89% | 30.32% |
| Panacea Biotec | ₹557.20 | — | 3,413 | 0.00% | −1 | +93.02% | 167 | +25.82% | −2.44% |
| Median: 157 Co. | ₹408.30 | 33.25 | 1,798 | 0.09% | 12 | +22.34% | 177 | +16.22% | 15.14% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013nseFinancial Year 2013bseFinancial Year 2012nse
Credit ratings6
Announcements5
Closure of Trading Window 2d - Trading window closed from July 1, 2026 until 48 hours after Q1 FY2027 results.Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011 17 JunAnnouncement under Regulation 30 (LODR)-Newspaper Publication 16 Jun - Please find attached newspaper copies regarding notice intimating the investors about the opening of a special window for transfer and dematerialisation of physical shares.Announcement under Regulation 30 (LODR)-Press Release / Media Release 8 Jun - Panacea launches DENSTAR project for DengiAll licensure in Africa; 48-month EU-funded initiative worth €11.09 million.Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011 5 Jun